<DOC>
	<DOC>NCT00355615</DOC>
	<brief_summary>The primary objective of this study is to determine the efficacy of once-daily rosuvastatin in reducing LDL-C in children and adolescents aged 10-17 years with HeFH from baseline (Day 0) to the end of the 12-week double-blind treatment period.</brief_summary>
	<brief_title>PLUTO: Pediatric Lipid-redUction Trial of rOsuvastatin</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type II</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Male or female (at least 1 year postmenarche) children and adolescents (aged 10 17 years) with heterozygous familial hypercholesterolemia (HeFH) Certain medical conditions and lab test results History of a reaction to rosuvastatin or other statin drugs Use of specified disallowed medications</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Heterozygous Familial Hypercholesterolemia</keyword>
</DOC>